Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)-Reference-Cited by-同舟云学术

Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)

Published:2024-01 Issue: Volume:187 Page:107441
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gridelli Cesare^ORCID,Peters Solange,Mok Tony,Garassino Marina,Paz-Ares Luis,Attili Ilaria,de Marinis Filippo

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the italian association of thoracic oncology;Gridelli;ESMO Open,2022

2. Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an international experts panel meeting by the italian association of thoracic oncology (AIOT);Gridelli;ESMO Open,2023

3. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N. Engl. J. Med.,2018

4. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer;Paz-Ares;N. Engl. J. Med.,2018

5. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-Year outcomes from the phase 3 keynote-189 study;Garassino;J Clin Oncol,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer;Journal of Experimental & Clinical Cancer Research;2024-08-07

2. Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis;JNCI: Journal of the National Cancer Institute;2024-06-17

3. Real-World Outcomes of Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer a Comparative Analysis with Keynote189 Clinical Trial;2024